MaaT013

MaaT Pharma presented promising preclinical data for MaaT034, a next-generation synthetic microbiome therapy designed to improve patient responses to cancer immunotherapies.

The microbiome therapeutics landscape shows remarkable growth with over 140 companies actively developing 180+ pipeline drugs, spanning various disease areas and therapeutic approaches.

MaaT Pharma's MaaT033, an oral microbiome therapy, maintains a positive safety profile in the Phase 2b PHOEBUS trial, as confirmed by the second DSMB review.

MaaT Pharma's share price surged over 19% following the announcement of successful Phase 3 clinical trial results for its MaaT013 treatment in acute graft-versus-host disease, marking a significant advancement in gastrointestinal response rates.

MaaT Pharma SA, a late-stage clinical company, is making significant progress in the development of gut microbiome-driven therapies aimed at modulating the immune system and improving cancer survival. The company's pipeline includes MaaT013, MaaT033, and MaaT03X, targeting acute graft versus host diseases, acute myeloid leukemia, and solid tumors, respectively.